Cancer News and Research

Latest Cancer News and Research

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

First Edition: September 22, 2010

Today's headlines focus on news surrounding tomorrow's six-month anniversary of the new health law and some of the specific provisions that will kick in on that day.

22 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Celsion Corporation announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

22 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

Protein zyxin necessary for maintenance and repair of cell's cytoskeleton

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered that a protein, zyxin, is necessary for the maintenance and repair of the cell's cytoskeleton, or internal framework, which serves as the muscle and bone of the cell. The research has implications for cancer, as well as other diseases, since alterations in the cytoskeleton are often associated with disease. The research was published in the Sep. 14, 2010, issue of the journal Developmental Cell.

22 Sep 2010

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

Philadelphia Inquirer: Efforts by N.J. Senate Democrats to restore $7.5 million to state family planning health centers ended Monday without any Republican support. In a 23-17 party line vote the Senate failed veto the governor's veto of center funding. Gov. "Christie's budget eliminated state funding to 58 family-planning health centers across the state, which last year provided services to more than 130,000 men and women, most of whom were underinsured.

22 Sep 2010

UT MD Anderson Cancer Center aims to reduce tobacco use among at-risk youths in SE Texas

The University of Texas MD Anderson Cancer Center is reaching out to southeast Texas via an interactive, arcade-style video game aimed at reducing tobacco use among at-risk teens and adolescents.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

Pancreas releases new NANETS guidelines on rare group of cancers

Neuroendocrine tumors (NETs) are a group of rare cancers that pose unique challenges in diagnosis and treatment. In a recent issue of Pancreas, official journal of the American Pancreatic Association, presents the newly developed consensus guidelines of the North American Neuroendocrine Tumor Society (NANETS).

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Dr. Shlomo Melmed awarded 9th Endocrine Regulation Prize of the Fondation Ipsen

The international jury under the presidency of Professor Iain Robinson (National Institute for Medical Research, London, UK) awarded today the 9th Endocrine Regulation Prize of the Fondation Ipsen (20.000€) to Dr. Shlomo Melmed (Cedars-Sinai Medical Center, Los Angeles, USA) during the annual congress of the ENEA (European NeuroEndocrine Association) in Liège (Belgium), for his translational approach to endocrinology. Shlomo Melmed is an internationally recognized endocrinologist and an authority on pituitary medicine.

22 Sep 2010

Islamic Relief USA provides $20 million medical aid to Pakistan

Islamic Relief USA (IR USA), a non-profit relief and development organization based in metro-D.C., announced today that it has delivered a $20 million aid shipment of medicine to Pakistan.

22 Sep 2010

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.

22 Sep 2010

Zyxin protein is critical to maintain and repair internal framework

22 Sep 2010

ARRA's legacies may solve challenges related to health, energy and environment

The presidents of six leading research universities and two higher-education associations joined Vice President Joe Biden and White House science advisor Dr. John Holdren this morning to discuss the scientific research and related activities that have been made possible by the American Recovery and Reinvestment Act (ARRA).

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

Physical or psychological stress before cancer treatment may sabotage therapy

Patients who experience physical or psychological stress - including rigorous exercise - one or two days before a cancer treatment might be unknowingly sabotaging their therapy, new research suggests.

22 Sep 2010

ACT people live longer but may have more mental health issues: Report

Chief Health Officer Charles Guest's report on the health and wellbeing of the Australian Capital Territory (ACT) population between July 2006 and June 2008 was presented in the Legislative Assembly. It showed that life expectancy rate at birth in the ACT was 80.3 years for males and 84 for women. This was despite the fact that most are overweight and only a minority eats enough fruit and vegetables.

22 Sep 2010

Cancer News and Research

Latest Cancer News and Research

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

First Edition: September 22, 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Protein zyxin necessary for maintenance and repair of cell's cytoskeleton

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

UT MD Anderson Cancer Center aims to reduce tobacco use among at-risk youths in SE Texas

AACR to host fourth International Conference on Molecular Diagnostics

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Pancreas releases new NANETS guidelines on rare group of cancers

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Dr. Shlomo Melmed awarded 9th Endocrine Regulation Prize of the Fondation Ipsen

Islamic Relief USA provides $20 million medical aid to Pakistan

Synthetic lethality boosts effectiveness of molecularly targeted therapies against tumors

Zyxin protein is critical to maintain and repair internal framework

ARRA's legacies may solve challenges related to health, energy and environment

Study demonstrates why targeted therapies do not work in majority of people

Physical or psychological stress before cancer treatment may sabotage therapy

ACT people live longer but may have more mental health issues: Report

Industry Focus - Oncology (1st Edition) eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus - Oncology (1st Edition) eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in